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Background: External beam radiotherapy is an effective, 
time-efficient, safe, and cost effective palliative treatment 
for patients with painful bone metastases. The importance of 
this therapeutic approach, coupled with complexities of 
multidisciplinary care, has led to three International 
Consensus Conference Workshops on Palliative 
Radiotherapy beginning in 1990 and reconvening every ten 
years since. The Third International Consensus Conference 
Workshop was convened in San Diego, California in 2010, and 
it and paved the way for the publication of the American 
Society for Radiation Oncology Bone Metastases Guidelines 
that confirmed the pain relief equivalency between 30 Gy in 
10 fractions, 24 Gy in 6 fractions, 20 Gy in 5 fractions, or a 
single 8 Gy fraction. 
Methods: Given the rapid rate of advancements in the 
management of these patients, the decision was made to 
shorten the interval between conferences and to host the 
Fourth International Consensus Conference Workshop at the 
2015 European Society for Radiation Oncology Meeting. This 
group will have the opportunity to discuss research updates 
that have been published since the 2010 International 
Conference. 
Results: The recent update on the systemic review of 
palliative radiotherapy trials for bone metastases by Chow et 
al confirms previous conclusions regarding the most 
appropriate fractionation schema. The re-analysis of 
Radiation Therapy and Oncology Group 97-14 data by Howell 
et al helps allay fears about late spinal cord toxicity for 
patients who receive a single 8 Gy fraction for spine bone 
metastases. The first prospective, randomized data about the 
safety and efficacy of re-treatment with external beam 
radiotherapy published by Chow et al provides guidance for 
the management of patients with recurrent pain to the same 
skeletal site. Additionally, the growing data for the most 
appropriate use of highly conformal therapy allows for 
updated recommendations for the treatment of spine bone 
metastases, especially in the setting of patients with more 
favorable prognoses and oligometastases. Lastly, a growing 
body of data helps to more accurately define the effective 
combination of external beam radiotherapy with 
radionuclides, bone strengthening agents, and kyphoplasty or 
vertebroplasty. 
Conclusion: The results of the 2015 ESTRO International 
Consensus Conference Workshop will help to shape the 
pathways for palliative radiotherapy investigation in the 
coming years, and it will set the stage for the Fifth 
Conference to be held in 2020. 
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Brain metastases occur in up to 40% of adult cancer patients 
during the course of their disease. About 60% of these 
patients have multiple brain metastases, mostly defined as 
>=4 (or >=5) lesions. The majority of these patients have a 
poor survival prognosis of only a few months. Without 
treatment, the median survival time is about 1 month, with 
corticosteroids alone about 1-2 months. Most of the patients 
with multiple lesions receive whole-brain radiotherapy 
(WBRT) alone resulting in median survival times of 3-6 
months in most series. Taking into account the generally poor 
survival prognosis, the overall treatment time of WBRT 
should be as short as possible. Retrospective studies have 
suggested that 5x4 Gy in 1 week is as effective as longer-
course programs such as 10x3 Gy in 2 weeks or 20x2 Gy in 4 
weeks in patients with a poor or intermediate survival 
prognosis. Patients with a more favorable prognosis may 
benefit from longer-course WBRT with total doses >30 Gy and 
doses per fraction <3 Gy. According to retrospective studies, 
total doses >30 Gy resulted in better intracerebral control 
and overall survival, doses per fraction <3 Gy in less 
neurocognitive deficits. In order to reduce the risk of 
neurocognitive decline, a recent study provided promising 
results achieved with sparing of the hippocampus. 
Since the appropriate fractionation of WBRT for the 
individual patient depends on the patient’s survival 
prognosis, prognostic tools that allow estimating the 
remaining lifetime are important. Several survival scores 
already exist. To be able to even better tailor the treatment 
regimen to each patient, separate survival scores have been 
developed for different primary tumor types leading to brain 
metastases, because each of these primary tumors has its 
own biological and clinical behavior. 
It has been shown that patients with a limited number of 1-3 
(or 1-4) brain metastases have a much more favorable 
survival prognosis than those patients with multiple lesions. 
Therefore, particularly these patients may benefit from more 
intensive treatments such as neurosurgical resection, 
stereotactic radiosurgery (SRS) and fractionated stereotactic 
radiotherapy (FSRT). SRS +/- WBRT has been shown to result 
in better local control of the treated lesions, better 
intracerebral control and better overall survival when 
compared to WBRT alone.  
SRS+WBRT has been demonstrated to result in better local 
control and intracerebral control without significant 
improvement in overall survival. Since a randomized trial of 
58 patients has demonstrated that the neurocognitive 
function was significantly worse after SRS+WBRT than after 
SRS alone at 4 months following treatment, many physicians 
are reserved regarding the addition of WBRT to SRS. 
However, in that randomized trial neurocognitive function 
was not evaluated at 12 months following treatment, when 
intracerebral control was significantly better after SRS+WBRT 
than after SRS alone (73% vs. 27%, p<0.001). Several authors 
have stated that an intracerebral recurrence (and not WBRT) 
is the most important cause of neurocognitive decline. In a 
prospective study from Japan, neurocognitive function 
appeared even better after SRS+WBRT than after SRS alone at 
1 year and at 2 years following treatment. Thus, the role of 
WBRT in addition to SRS needs to be better defined in further 
